Prehospital Statin Therapy and Outcomes in ST-Elevation Myocardial Infarction Undergoing Primary Percutaneous
Kei Inutsuka1, Eiji Shibahashi1, Hisao Otsuki1
1Department of Cardiology, Tokyo Women's Medical University, Tokyo, Japan.
Insights
Prehospital statin therapy before ST-elevation myocardial infarction (STEMI) is linked to better outcomes. Patients receiving statins prior to STEMI showed significantly lower 1-year major adverse cardiovascular events after primary percutaneous coronary intervention.
Area of Science:
- Cardiology
- Cardiovascular Research
- Clinical Trials
Background:
- The impact of prehospital statin therapy on ST-elevation myocardial infarction (STEMI) patients undergoing primary percutaneous coronary intervention (PCI) is not fully understood.
- Assessing the association between pre-treatment statin use and patient outcomes is crucial for optimizing STEMI management.
Purpose of the Study:
- To evaluate if prehospital statin administration is associated with reduced 1-year cardiovascular event rates in STEMI patients.
- To determine the impact of prior statin use on major adverse cardiovascular events (MACE) following primary PCI.
Main Methods:
- Analysis of data from 827 consecutive STEMI patients undergoing primary PCI from a multicenter registry.
- Patients were categorized into prior statin (n=510) and non-prior statin (n=317) groups.
- Inverse probability of treatment weighting (IPTW) was employed for primary analysis, with multivariable Cox regression and sensitivity analyses used for validation.
Main Results:
- After IPTW adjustment, the prior statin group exhibited significantly lower weighted 1-year MACE incidence (3.1% vs. 7.6%).
- The hazard ratio for MACE in the prior statin group was 0.31 (95% CI, 0.17-0.57).
- This association remained consistent across various statistical analyses, including multivariable Cox regression.
Conclusions:
- Prehospital statin therapy prior to STEMI onset is associated with a significant reduction in 1-year cardiovascular event rates after primary PCI.
- The observed benefit, primarily driven by decreased mortality, supports the use of statins before STEMI events.
- Findings suggest that initiating statin therapy before myocardial infarction may improve long-term outcomes in patients undergoing primary PCI.
Abstract:
Whether prehospital statin therapy is associated with better outcomes in patients with ST-elevation myocardial infarction (STEMI) undergoing primary percutaneous coronary intervention (PCI) remains unclear. We evaluated the association between previous statin use and lower 1-year cardiovascular event rates in this population. We analyzed data from 827 consecutive patients with STEMI undergoing primary PCI from a multicenter registry and classified them into a prior statin group (n = 510, 62%) and a nonprior statin group (n = 317, 38%). The primary endpoint was 1-year major adverse cardiovascular events (MACE), defined as cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke. Inverse probability of treatment weighting (IPTW) was the primary analytic approach. After IPTW adjustment, the prior statin group had a lower weighted 1-year MACE incidence than the nonprior statin group (3.1% vs 7.6%; hazard ratio, 0.31; 95% confidence interval, 0.17 to 0.57). The association between previous statin therapy and lower MACE risk was consistent in multivariable Cox regression and sensitivity analyses using modified IPTW approaches. In conclusion, statin therapy before STEMI onset was associated with lower 1-year cardiovascular event rates after primary PCI, a finding mainly driven by lower mortality.
Related Concept Videos
01:28Acute Coronary Syndrome IV: Interprofessional Care
01:30Acute Coronary Syndrome I: Introduction
01:27Coronary Artery Disease V: Interprofessional Care
01:30Acute Coronary Syndrome III: Diagnostic Studies
01:26Angina IV: Management
01:26Atherosclerosis III: Management